On-X机械主动脉瓣膜出血与血栓栓塞事件:SWEDEHEART研究
这项基于SWEDEHEART登记的国家队列研究纳入2014-2022年瑞典3047例首次机械主动脉瓣置换成人,比较On-X瓣膜与其他机械瓣膜的主要出血和血栓栓塞事件。经加权后8年主要出血累积发生率On-X组7.2%对其他机械瓣组7.0%,血栓栓塞事件累积发生率On-X组7.3%对其他机械瓣组6.4%。结论认为On-X主动脉瓣与其他机械主动脉瓣相比,主要出血或血栓栓塞事件无临床相关差异。
要点
- On-X组8年加权主要出血累积发生率为7.2%,其他机械瓣组为7.0%。
- On-X组8年加权血栓栓塞事件累积发生率为7.3%,其他机械瓣组为6.4%。
- 研究未发现On-X瓣膜与其他机械主动脉瓣在主要出血或血栓栓塞事件上有临床相关差异。
核心结论
- On-X主动脉瓣与其他机械主动脉瓣相比,主要出血或血栓栓塞事件无临床相关差异。
研究设计与样本
- 全国性、基于人群的队列研究,采用目标试验模拟框架。
- 纳入2014-2022年瑞典SWEDEHEART登记中所有首次机械主动脉瓣置换的成人,共3047例。
- 656例(22%)接受On-X主动脉瓣,2391例(78%)接受其他机械主动脉瓣;平均年龄54岁,女性占23%。
- 通过加权处理混杂因素,主要出血和血栓栓塞事件发生率来自国家登记。
主要发现
- 8年后加权主要出血累积发生率:On-X组7.2%(95% CI: 4.8%-10.7%),其他机械瓣组7.0%(95% CI: 5.5%-8.8%)。
- 8年后加权血栓栓塞事件累积发生率:On-X组7.3%(95% CI: 5.3%-10.2%),其他机械瓣组6.4%(95% CI: 5.0%-7.9%)。
临床怎么用
- On-X主动脉瓣虽获批较低INR目标(1.5-2.0),但本研究未显示其较其他机械主动脉瓣在主要出血或血栓栓塞事件上有临床相关获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Lifelong anticoagulation therapy is mandatory in patients with mechanical heart valves. The On-X aortic valve is currently the only mechanical heart valve approved for a lower (1.5-2.0) target international normalized ratio (INR) compared to the standard INR target 2.0-3.0. There is limited evidence demonstrating clinical benefits of the On-X valve over other mechanical aortic valves. We therefore investigated the risk of bleeding and thromboembolic events in patients with the On-X aortic valve. METHODS: This nationwide, population-based cohort study, using the target trial emulation framework, included all adults who underwent primary mechanical aortic valve replacement in Sweden 2014-2022 from the SWEDEHEART register. The rates of major bleeding and thromboembolic events were obtained from national registers. Confounding was addressed by weighting. RESULTS: Of the 3047 patients, 656 patients (22%) received an On-X aortic valve and 2391 patients (78%) received other mechanical aortic valves. The mean age was 54 years and 23% were women. After 8 years, the weighted major bleeding cumulative incidence was 7.2% (95% CI: 4.8%-10.7%) in the On-X valve group vs 7.0% (95% CI: 5.5%-8.8%) in the other mechanical valves group, and the weighted cumulative incidence of thromboembolic events was 7.3% (95% CI: 5.3%-10.2%) in the On-X valve group vs 6.4% (95% CI: 5.0%-7.9%) in the other mechanical valves group. CONCLUSIONS: We found no clinically relevant difference in major bleeding or thromboembolic events in patients with the On-X aortic valve compared to patients with other mechanical aortic valves.
引用
- Lu R, Dismorr M, Dalén M, et al. Major Bleeding and Thromboembolic Events with the On-X Mechanical Aortic Valve Prosthesis: A SWEDEHEART Study. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40729308. doi:10.1093/icvts/ivaf182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。